Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting research on its Axumin (fluciclovine F-18) PET radiopharmaceutical at the upcoming American Society for Clinical Oncology Genitourinary (ASCO GU) virtual meeting.
Research will cover the diagnostic utility of fluciclovine F-18 PET in biochemically recurrent prostate cancer based on prior primary treatment modality for localized disease and the impact of those findings on treatment, using fluciclovine F-18 PET/CT for prostate cancer, and fluciclovine F-18 PET in metastatic castration-resistant prostate cancer treated with abiraterone acetate.
